Year: 2014

STRATEGIC CONVERSATIONS AT ISPOR MEETINGS CONTINUE TO DRIVE RECORD ATTENDANCE; EBOLA PAPER ANNOUNCED

(Princeton, NJ USA  December 22, 2014)  – The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) released comments about its 17th Annual European Congress which drew record-breaking attendance in Amsterdam from November 10-12, 2014.  More than 4,800 researchers, decision makers, and health technology

Posted in Announcements, ISPOR News & Press, Uncategorized Tagged with: ,

CURRENT PRACTICE OF RCT-BASED MODELLING CAN LEAD TO WRONG RESEARCH PRIORITIES

Rotterdam, The Netherlands – The current practice of prioritizing research in the context of conditional reimbursement can lead to wrong decisions since it relies on randomized controlled trials (RCT) based cost-effectiveness models, which do not reflect all uncertainties that are

Posted in Methodological Articles, Value in Health Tagged with: , , , , ,

“MORE DOCTORS” … FROM ABROAD: A SOLUTION FOR PHYSICIAN MALDISTRIBUTION?

Porto Alegre, Brazil – Social problems, including health care concerns, led millions of people to protest on the streets of Brazil in 2014. Brazil has approximately 18 doctors per 10,000 inhabitants, a number that is above the world’s average of

Posted in Commentary, Value in Health Regional Issues Tagged with: ,

THE VALUE OF GENETIC DIVINATION – STATED PREFERENCES FOR PERSONALIZED INFORMATION FOR REDUCING MORTALITY RISKS

Durham, NC, USA – The advent of genetic testing provides individuals and health care systems the opportunity to acquire information about predispositions to cancers and other diseases.  Whether this information is useful depends on the existence of efficacious health interventions

Posted in Announcements, Preference-Based Assessments, Value in Health Tagged with: , , , , , ,

HOW DO PUBLIC HEALTH INSTITUTIONS DECIDE WHICH HEALTH TECHNOLOGIES ARE AVAILABLE IN MEXICO?

Mexico City, Mexico – Since improving the process for the submission of new health technologies in 2011, the Mexican Public Health Institution has also optimized public resources through the use of technologies (supplies) that have proven their safety, therapeutic efficacy,

Posted in Health Policy Analyses, Value in Health Regional Issues Tagged with: , , , ,

WHAT`S GOING ON WITH THE TURKISH ORPHAN DRUGS MARKET?

Ankara, Turkey – Many countries and regions have already defined health policies on orphan drugs for rare diseases. Although there is no official definition in Turkey, all orphan drugs are covered by reimbursement, regardless of their market authorization status.

Posted in Announcements, Health Policy Analyses, Value in Health Regional Issues Tagged with: , , , , , , , ,